Celularity Inc. Appoints Naveen Jain to Board; Diane Parks to Resign

What Happened Celularity Inc. announced on September 29, 2026 that the Board appointed Naveen Jain to serve as a director, with his term to begin upon the expiration of the waiting period after the filing and mailing of an Information Statement required under Section 14(f) of the Exchange Act (the “Effective Time”). Mr. Jain was designated for the seat under board-designation rights tied to the Company’s September 2026 financing. In connection with this appointment, director Diane Parks notified the Company she will resign from the Board effective as of the Effective Time; her resignation is not due to any disagreement with the Company.

Mr. Jain is founder and CEO of Viome Life Sciences and previously founded InfoSpace, Intelius, TalentWise and Moon Express. The Company said there are no family relationships or reportable transactions between Mr. Jain and Celularity, and he will participate in Celularity’s standard non-employee director compensation and is expected to sign the standard indemnification agreement. He has not been initially assigned to any Board committee.

Key Details

• Filing date: Form 8-K filed September 29, 2026.
• Effective Time: Appointment and resignation become effective after the Information Statement waiting period under Section 14(f) / Rule 14f-1.
• Source of designation: Mr. Jain’s appointment stems from board-designation rights granted to investors in Celularity’s September 2026 financing (previously disclosed on 9/28/2026).
• Governance: Mr. Jain will receive standard non-employee director compensation and expected to enter the Company’s standard director/officer indemnification agreement; no committee assignments initially. Diane Parks’ resignation is not due to any disagreement with Celularity.

Why It Matters Changes to the Board affect corporate governance and who helps set oversight and strategic direction. This appointment reflects investor influence tied to the recent financing (board-designation rights) rather than an internal management change, and the Company disclosed no related-party transactions with Mr. Jain. For investors, monitor future disclosures for any committee assignments, strategic statements, or governance changes that follow this Board change.